XML 20 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net income (loss) $ 172,286 $ (1,402,433)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization expense 1,255,675 1,653,746
Share-based compensation 90,156 159,901
Decrease in non-cash contingent consideration (267,637) 370,464
Decrease (increase) in cash surrender value of life insurance policies over premiums paid (30,799) 222,209
Increase in noncash interest expense 4,296 2,183
Gain on receivable of FDA fees (1,847,065) 0
Net changes in assets and liabilities affecting operating activities:    
Accounts receivable 481,613 (7,758,089)
Inventories (323,557) 2,271,484
Other current assets and other assets 682,958 239,862
Accounts payable and other current liabilities (1,105,263) 4,461,389
Other long-term liabilities (530,872) (371,214)
Net cash used in operating activities (1,418,209) (150,498)
Cash flows from investing activities:    
Additions to property and equipment (107,260) (26,986)
Cash paid for acquisitions 0 (13,500,000)
Additions to intangible assets (67,193) (14,912)
Net cash used in investing activities (174,453) (13,541,898)
Cash flows from financing activities:    
Borrowings on line of credit 8,000,000 20,000,000
Repayments on line of credit (8,127,714) (15,000,000)
Cash payment of contingent consideration (1,464,311) (501,505)
Repurchase of common shares (187,117) (580,130)
Net cash provided by (used in) financing activities (1,779,142) 3,918,365
Net decrease in cash and cash equivalents (3,371,804) (9,774,031)
Cash and cash equivalents at beginning of period 19,757,970 27,040,816
Cash and cash equivalents at end of period $ 16,386,166 $ 17,266,785